MX395521B - Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas - Google Patents
Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estasInfo
- Publication number
- MX395521B MX395521B MX2018012224A MX2018012224A MX395521B MX 395521 B MX395521 B MX 395521B MX 2018012224 A MX2018012224 A MX 2018012224A MX 2018012224 A MX2018012224 A MX 2018012224A MX 395521 B MX395521 B MX 395521B
- Authority
- MX
- Mexico
- Prior art keywords
- valproic acid
- pharmaceutical formulations
- delayed release
- release pharmaceutical
- pharmaceutically acceptable
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000604 valproic acid Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000003111 delayed effect Effects 0.000 title 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606197 | 2016-04-08 | ||
| PCT/GB2017/051002 WO2017175013A1 (en) | 2016-04-08 | 2017-04-10 | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012224A MX2018012224A (es) | 2019-05-16 |
| MX395521B true MX395521B (es) | 2025-03-25 |
Family
ID=58709491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012224A MX395521B (es) | 2016-04-08 | 2017-04-10 | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11395808B2 (https=) |
| EP (1) | EP3439649B1 (https=) |
| JP (1) | JP6985368B2 (https=) |
| KR (1) | KR102438395B1 (https=) |
| CN (2) | CN109414423A (https=) |
| AU (1) | AU2017246697B2 (https=) |
| CA (1) | CA3018043A1 (https=) |
| ES (1) | ES2969021T3 (https=) |
| HU (1) | HUE064701T2 (https=) |
| IL (1) | IL262163B2 (https=) |
| MX (1) | MX395521B (https=) |
| PL (1) | PL3439649T3 (https=) |
| RU (1) | RU2760304C2 (https=) |
| WO (1) | WO2017175013A1 (https=) |
| ZA (1) | ZA201806766B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CA3018043A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| US20240285636A1 (en) * | 2021-06-14 | 2024-08-29 | Libbs Farmacêutica Ltda | Pharmaceutical composition and use of the pharmaceutical composition |
| CN113995742B (zh) * | 2021-10-22 | 2023-12-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 包含丙戊酸的美白组合物及其用途 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
| WO2026068561A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Valproic acid for use in treating pulmonary arterial hypertension |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE68346T1 (de) | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| CN1228043C (zh) * | 1999-09-30 | 2005-11-23 | 爱德华·孟岱尔股份有限公司 | 用于高溶解度药物的缓释基质 |
| AT408718B (de) * | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| EP1937236A2 (en) | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| TWI393708B (zh) | 2005-09-08 | 2013-04-21 | Mei Pharma Inc | 異羥肟酸脂化合物，其用途及其之合成方法 |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| DE602006003848D1 (de) * | 2006-01-11 | 2009-01-08 | Teva Pharma | Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| US20090312311A1 (en) | 2006-04-06 | 2009-12-17 | Gary Michael Ksander | Combination of organic compounds |
| US20080069878A1 (en) | 2006-08-31 | 2008-03-20 | Gopi Venkatesh | Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| CN101947209B (zh) * | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| DK2683371T3 (da) * | 2011-03-09 | 2021-01-18 | Cereno Scient Ab | Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere |
| JP6330118B2 (ja) | 2011-09-13 | 2018-05-30 | ファーマサイクリックス エルエルシー | ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用 |
| CN104248627A (zh) * | 2013-06-25 | 2014-12-31 | 北大方正集团有限公司 | 丙戊酸半钠泡腾干混悬剂及其制备方法 |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CA3018043A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| WO2017175010A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
-
2017
- 2017-04-10 CA CA3018043A patent/CA3018043A1/en active Pending
- 2017-04-10 CN CN201780025746.XA patent/CN109414423A/zh active Pending
- 2017-04-10 KR KR1020187031904A patent/KR102438395B1/ko active Active
- 2017-04-10 US US16/090,664 patent/US11395808B2/en active Active
- 2017-04-10 MX MX2018012224A patent/MX395521B/es unknown
- 2017-04-10 PL PL17723734.4T patent/PL3439649T3/pl unknown
- 2017-04-10 RU RU2018137399A patent/RU2760304C2/ru active
- 2017-04-10 EP EP17723734.4A patent/EP3439649B1/en active Active
- 2017-04-10 AU AU2017246697A patent/AU2017246697B2/en active Active
- 2017-04-10 JP JP2019503794A patent/JP6985368B2/ja active Active
- 2017-04-10 WO PCT/GB2017/051002 patent/WO2017175013A1/en not_active Ceased
- 2017-04-10 CN CN202111575415.8A patent/CN114209667A/zh active Pending
- 2017-04-10 HU HUE17723734A patent/HUE064701T2/hu unknown
- 2017-04-10 ES ES17723734T patent/ES2969021T3/es active Active
-
2018
- 2018-10-07 IL IL262163A patent/IL262163B2/en unknown
- 2018-10-11 ZA ZA2018/06766A patent/ZA201806766B/en unknown
-
2022
- 2022-07-19 US US17/868,323 patent/US12023311B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017246697A1 (en) | 2018-10-04 |
| AU2017246697B2 (en) | 2022-06-02 |
| JP6985368B2 (ja) | 2021-12-22 |
| IL262163B1 (en) | 2023-03-01 |
| IL262163A (en) | 2018-11-29 |
| BR112018070626A2 (pt) | 2019-02-05 |
| EP3439649C0 (en) | 2023-11-15 |
| NZ746269A (en) | 2024-10-25 |
| RU2018137399A (ru) | 2020-05-12 |
| RU2018137399A3 (https=) | 2020-06-18 |
| US20190111011A1 (en) | 2019-04-18 |
| US20230120670A1 (en) | 2023-04-20 |
| RU2760304C2 (ru) | 2021-11-23 |
| EP3439649A1 (en) | 2019-02-13 |
| CN114209667A (zh) | 2022-03-22 |
| HUE064701T2 (hu) | 2024-04-28 |
| KR20180127480A (ko) | 2018-11-28 |
| IL262163B2 (en) | 2023-07-01 |
| EP3439649B1 (en) | 2023-11-15 |
| JP2019510834A (ja) | 2019-04-18 |
| ES2969021T3 (es) | 2024-05-16 |
| PL3439649T3 (pl) | 2024-03-18 |
| US12023311B2 (en) | 2024-07-02 |
| US11395808B2 (en) | 2022-07-26 |
| CN109414423A (zh) | 2019-03-01 |
| ZA201806766B (en) | 2024-03-27 |
| WO2017175013A1 (en) | 2017-10-12 |
| CA3018043A1 (en) | 2017-10-12 |
| MX2018012224A (es) | 2019-05-16 |
| KR102438395B1 (ko) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395521B (es) | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| WO2017037594A3 (zh) | 用于减少局部脂肪的医药组成物及其用途 | |
| AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| MY187358A (en) | Modified release orally administered amino acid formulations | |
| PH12017502376B1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CL2017001840A1 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. | |
| PH12018502089A1 (en) | Pharmaceutical composition of dapagliflozin | |
| EP4257149A3 (en) | Stable liquid gonadotropin formulation | |
| GEAP202215306A (en) | Formulations of copanlisib | |
| WO2019240699A3 (en) | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion | |
| GEP20196977B (en) | Pharmaceutical formulations of vildagliptin | |
| AU2017277002A1 (en) | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| WO2019209217A3 (en) | Modified release formulations of flurbiprofen | |
| MX2021016053A (es) | Formulaciones de espuma rectal. | |
| WO2019125166A3 (en) | Hyaluronic acid formulations | |
| PL419082A1 (pl) | Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol | |
| TN2016000561A1 (en) | Stabilized desmopressin | |
| EA202090803A1 (ru) | Фармацевтическая композиция адапалена и миноциклина для наружного применения | |
| UA91650U (uk) | Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул |